Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2021 Filed Feb 4, 2021 00:54 UTC |
Culwell KellyChief Medical Officer
|
GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001618835-21-000007 · wf-form4_161240003886283.xml · derivative · entry 2 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-02-03 F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 3, 2021. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 00:54 UTC |
Culwell KellyChief Medical Officer
|
GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-21-000007 · wf-form4_161240003886283.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,451 F1 · shares: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2021. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 17:22 UTC |
File Justin J.Chief Financial Officer
|
PurchaseCommon Stock | 7,760 | $2.17 | $16,839.20 |
DisclosureSEC source: 0001618835-20-000248 · wf-form4_160573815596283.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,168 F1 · security: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.16 to $2.18, inclusive. The reporting person undertakes to provide to Evofem Biosciences, Inc. (Evofem), any security holder of Evofem, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 17:14 UTC |
Fitzpatrick Alexander AGeneral Counsel and Secretary
|
PurchaseCommon Stock | 9,090 | $2.20 | $19,998.00 |
DisclosureSEC source: 0001618835-20-000246 · wf-form4_160573767675790.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,542 Read SEC document |
| September 11, 2020 Filed Sep 11, 2020 21:20 UTC |
Barrans RussellChief Commercial Officer
|
PurchaseCommon Stock | 3,000 | $2.08 | $6,240.00 |
DisclosureSEC source: 0001618835-20-000220 · wf-form4_159985918676264.xml · nonDerivative · entry 2 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,052 Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 21:20 UTC |
Barrans RussellChief Commercial Officer
|
PurchaseCommon Stock | 1,000 | $2.71 | $2,710.00 |
DisclosureSEC source: 0001618835-20-000220 · wf-form4_159985918676264.xml · nonDerivative · entry 1 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,052 Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:04 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
SaleCommon Stock | 122,500 | $3.26 | $399,350.00 |
DisclosureSEC source: 0001618835-20-000218 · wf-form4_159978266397349.xml · nonDerivative · entry 1 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,888 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.09 to $3.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · balance_after: The total amount of securities beneficially owned includes 4,303 shares of common stock the reporting person purchased in accordance with the 2019 ESPP based on 85% of the closing stock price on June 12,2020, the last trading day of the purchase period. Read SEC document |
| July 08, 2020 Filed Jul 9, 2020 22:17 UTC |
Barrans RussellChief Commercial Officer
|
Tax withholdingCommon Stock | 20,381 | $3.30 | $67,257.30 |
DisclosureSEC source: 0001618835-20-000206 · wf-form4_159433301888130.xml · nonDerivative · entry 1 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,052 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on July 8, 2020. No shares were sold in connection with this transaction. F2 · balance_after: The total amount of securities beneficially owned includes 1,924 shares of common stock the reporting person purchased in accordance with the 2019 ESPP based on 85% of the closing stock price on June 12,2020, the last trading day of the purchase period. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:29 UTC |
Rarick Lisa DaleDirector
|
PurchaseCommon Stock | 5,250 | $2.99 | $15,697.50 |
DisclosureSEC source: 0001618835-20-000204 · wf-form4_159251217994076.xml · nonDerivative · entry 1 Rarick Lisa Dale · CIK 0001803550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:38 UTC |
Hall William WalmsleyDirector
|
PurchaseCommon Stock | 5,000 | $2.85 | $14,250.00 |
DisclosureSEC source: 0001618835-20-000198 · wf-form4_159244068645749.xml · nonDerivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions. The reporting person undertakes to provide to Evofem Biosciences, Inc. (Evofem), any security holder of Evofem, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 16:29 UTC Amendment |
Hall William WalmsleyDirector
|
PurchaseCommon Stock | 5,000 | $2.85 | $14,250.00 |
DisclosureSEC source: 0001618835-20-000203 · wf-form4a_159251215883461.xml · nonDerivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The original Form 4, filed on June 17,2020, is being amended to update the price range reported in Column 4 of Table I. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.845 to $2.85, inclusive. The reporting person undertakes to provide to Evofem Biosciences, Inc. (Evofem), any security holder of Evofem, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 16:16 UTC |
File Justin J.Chief Financial Officer
|
PurchaseCommon Stock | 8,500 | $3.14 | $26,690.00 |
DisclosureSEC source: 0001618835-20-000194 · wf-form4_159225215860208.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,408 F1 · balance_after: The total amount of securities beneficially owned includes 4,303 shares of common stock the reporting person purchased in accordance with the 2019 ESPP based on 85% of the closing stock price on June 12,2020, the last trading day of the purchase period. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 20:35 UTC |
Kamdar Kim P.Director · 10% owner
|
PurchaseCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0001618835-20-000196 · wf-form4_159233969119430.xml · nonDerivative · entry 1 Kamdar Kim P. · CIK 0001535065 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,287 Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:43 UTC |
File Justin J.Chief Financial Officer
|
Tax withholdingCommon Stock | 42,810 | $3.31 | $141,701.10 |
DisclosureSEC source: 0001618835-20-000189 · wf-form4_159165258593749.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,605 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on June 5, 2020. No shares were sold in connection with this transaction. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:42 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 85,620 | $3.31 | $283,402.20 |
DisclosureSEC source: 0001618835-20-000187 · wf-form4_159165254089208.xml · nonDerivative · entry 1 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,085 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on June 5, 2020. No shares were sold in connection with this transaction. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:41 UTC |
Fitzpatrick Alexander AGeneral Counsel and Secretary
|
Tax withholdingCommon Stock | 31,590 | $3.31 | $104,562.90 |
DisclosureSEC source: 0001618835-20-000185 · wf-form4_159165249625617.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,452 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on June 5, 2020. No shares were sold in connection with this transaction. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 21:43 UTC |
Culwell KellyChief Medical Officer
|
Tax withholdingCommon Stock | 31,548 | $3.31 | $104,423.88 |
DisclosureSEC source: 0001618835-20-000188 · wf-form4_159165256285979.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,451 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on June 5, 2020. No shares were sold in connection with this transaction. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 21:42 UTC |
Barrans RussellChief Commercial Officer
|
Tax withholdingCommon Stock | 15,455 | $3.31 | $51,156.05 |
DisclosureSEC source: 0001618835-20-000186 · wf-form4_159165251807510.xml · nonDerivative · entry 1 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,509 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on June 5, 2020. No shares were sold in connection with this transaction. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 10:49 UTC |
Invesco Ltd.10% owner
|
PurchaseCommon stock | 857,143 | $3.50 | $3,000,000.50 |
DisclosureSEC source: 0001209191-20-035184 · doc4.xml · nonDerivative · entry 5 Invesco Ltd. · CIK 0000914208 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes 2 Disclosed balance after: 13,226,532 F2 · kind: On June 5, 2020, Invesco Ltd., through its affiliates, the Invesco High Income Fund (UK) and the Invesco Income Fund (UK), purchased 589,302 and 267,841, respectively, of the Issuer's common stock at a price of $3.50 per share as part of the Issuer's registered public offering of 28,500,000 shares. F3 · kind: Invesco Ltd. is aware that, under Section 16(b) of the Securities and Exchange Act of 1934, as amended, certain of the sales are matachable against certain purchases of Common Stock. Invesco Ltd. has calculated the aggregate profit to be $174,140.20, using the lowest possible purchase prices and the highest possible sales prices for such trades, and accordingly intends to remit payment to the Company in that amount less transaction costs. Read SEC document |
| June 04, 2020 Filed Jun 10, 2020 01:08 UTC |
ACACIA RESEARCH CORP10% owner
|
SaleCommon Stock, par value $0.0001 per share | 9,138,504 | $3.21 | $29,325,459.34 |
DisclosureSEC source: 0000902664-20-002335 · ownership.xml · nonDerivative · entry 1 ACACIA RESEARCH CORP · CIK 0000934549 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| June 04, 2020 Filed Jul 17, 2020 15:11 UTC |
Link Fund Solutions Ltd10% owner
|
SaleCommon Stock, par value $0.0001 per share | 9,138,504 | $0.23 | $2,101,855.92 |
DisclosureSEC source: 0000899243-20-019497 · doc4.xml · nonDerivative · entry 1 Link Fund Solutions Ltd · CIK 0001792424 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.2608 U.S. Dollars as of June 4, 2020. Read SEC document |
| May 26, 2020 Filed Jun 9, 2020 10:49 UTC |
Invesco Ltd.10% owner
|
SaleCommon stock | 65 | $5.98 | $388.70 |
DisclosureSEC source: 0001209191-20-035184 · doc4.xml · nonDerivative · entry 4 Invesco Ltd. · CIK 0000914208 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes 1 Disclosed balance after: 12,369,389 Read SEC document |
| May 26, 2020 Filed Jun 9, 2020 10:49 UTC |
Invesco Ltd.10% owner
|
SaleCommon stock | 73,814 | $5.79 | $427,383.06 |
DisclosureSEC source: 0001209191-20-035184 · doc4.xml · nonDerivative · entry 3 Invesco Ltd. · CIK 0000914208 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes 1 Disclosed balance after: 12,369,454 Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:15 UTC |
File Justin J.Chief Financial Officer
|
Tax withholdingCommon Stock | 42,262 | $4.99 | $210,887.38 |
DisclosureSEC source: 0001618835-20-000155 · wf-form4_159052772480668.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,415 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 22, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:17 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 84,525 | $4.99 | $421,779.75 |
DisclosureSEC source: 0001618835-20-000159 · wf-form4_159052781756168.xml · nonDerivative · entry 1 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,705 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 22, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:16 UTC |
Fitzpatrick Alexander AGeneral Counsel and Secretary
|
Tax withholdingCommon Stock | 39,487 | $4.99 | $197,040.13 |
DisclosureSEC source: 0001618835-20-000158 · wf-form4_159052779414010.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,042 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 22, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:16 UTC |
Culwell KellyChief Medical Officer
|
Tax withholdingCommon Stock | 39,435 | $4.99 | $196,780.65 |
DisclosureSEC source: 0001618835-20-000157 · wf-form4_159052777118613.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,999 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 22, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:16 UTC |
Barrans RussellChief Commercial Officer
|
Tax withholdingCommon Stock | 19,474 | $4.99 | $97,175.26 |
DisclosureSEC source: 0001618835-20-000156 · wf-form4_159052774810234.xml · nonDerivative · entry 1 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,964 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 22, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:43 UTC |
PDL BIOPHARMA, INC.10% owner
|
OtherCommon Stock | 13,333,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014185 · doc4.xml · nonDerivative · entry 1 PDL BIOPHARMA, INC. · CIK 0000882104 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents a pro rata distribution in-kind of the shares formerly held by the Reporting Person to its stockholders for no consideration. Read SEC document |
| May 15, 2020 Filed Jun 9, 2020 10:49 UTC |
Invesco Ltd.10% owner
|
SaleCommon stock | 3,211 | $5.04 | $16,183.44 |
DisclosureSEC source: 0001209191-20-035184 · doc4.xml · nonDerivative · entry 2 Invesco Ltd. · CIK 0000914208 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes 1 Disclosed balance after: 12,443,268 Read SEC document |
| May 14, 2020 Filed Jun 9, 2020 10:49 UTC |
Invesco Ltd.10% owner
|
OtherCommon stock | 78,013 | $5.13 | $400,206.69 |
DisclosureSEC source: 0001209191-20-035184 · doc4.xml · nonDerivative · entry 1 Invesco Ltd. · CIK 0000914208 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes 1 Disclosed balance after: 12,446,479 F1 · kind: Invesco Ltd. acquired the following common shares through its affiliates in a spin off transaction (the "Spin Off Transaction") on May 14, 2020: Invesco FTSE RAFI US 1500 Small-Mid ETF (73,814 shares of common stock); Invesco Buyback Achievers ETF (3,257 shares of common stock); LongView Broad Market 3000 Index Fund (Amalgamated) (923 shares of common stock); and Invesco Purebeta MSCI USA Small Cap ETF (19 shares of common stock). On May 15, 2020 the Invesco Buyback Achievers ETF sold 3,211 shares of Common Stock. On May 26, 2020, the Invesco FTSE RAFI US 1500 Small-Mid ETF sold 73,814 shares of Common Stock, the Invesco Buyback Achievers ETF sold 46 shares of Common Stock and the Invesco Purebeta MSCI USA Small Cap ETF sold 19 shares. Read SEC document |
| May 12, 2020 Filed May 13, 2020 16:40 UTC |
Rutherford ColinDirector
|
GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001618835-20-000138 · wf-form4_158940243940813.xml · derivative · entry 1 Rutherford Colin · CIK 0001726264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2020. The option was awarded in connection with Mr. Rutherford's board and committee services. Read SEC document |
| May 12, 2020 Filed May 13, 2020 16:39 UTC |
Hall William WalmsleyDirector
|
GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001618835-20-000133 · wf-form4_158940232263709.xml · derivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2020. The option was awarded in connection with Dr. Hall's board and committee services. Read SEC document |
| May 12, 2020 Filed May 13, 2020 16:40 UTC |
Greer GillianDirector
|
GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001618835-20-000136 · wf-form4_158940239482771.xml · derivative · entry 1 Greer Gillian · CIK 0001726181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2020. The option was awarded in connection with Dr. Greer's board and committee services. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:39 UTC |
Kamdar Kim P.Director · 10% owner
|
GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001618835-20-000134 · wf-form4_158940234764353.xml · derivative · entry 1 Kamdar Kim P. · CIK 0001535065 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2020. The option was awarded in connection with Dr. Kamdar's board and committee services. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:40 UTC |
O'Brien Anthony StephenDirector
|
GrantCommon Stock · Derivative | 50,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001618835-20-000137 · wf-form4_158940241739274.xml · derivative · entry 1 O'Brien Anthony Stephen · CIK 0001726732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2020. The option was awarded in connection with Mr. O'Brien's board and committee services. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:39 UTC |
Rarick Lisa DaleDirector
|
GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001618835-20-000135 · wf-form4_158940237371677.xml · derivative · entry 1 Rarick Lisa Dale · CIK 0001803550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2020. The option was awarded in connection with Dr. Rarick's board and committee services. Read SEC document |
| May 06, 2020 Filed May 8, 2020 12:31 UTC |
File Justin J.Chief Financial Officer
|
Tax withholdingCommon Stock | 8,420 | $5.24 | $44,120.80 |
DisclosureSEC source: 0001618835-20-000113 · wf-form4_158895547746701.xml · nonDerivative · entry 1 File Justin J. · CIK 0001726277 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,677 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 6, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 06, 2020 Filed May 8, 2020 12:31 UTC |
PELLETIER SAUNDRA LDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 16,905 | $5.24 | $88,582.20 |
DisclosureSEC source: 0001618835-20-000112 · wf-form4_158895545390049.xml · nonDerivative · entry 1 PELLETIER SAUNDRA L · CIK 0001251371 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,230 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 6, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 06, 2020 Filed May 8, 2020 16:32 UTC |
Barrans RussellChief Commercial Officer
|
Tax withholdingCommon Stock | 3,802 | $5.24 | $19,922.48 |
DisclosureSEC source: 0001618835-20-000115 · wf-form4_158895552459899.xml · nonDerivative · entry 1 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,438 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 6, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 06, 2020 Filed May 8, 2020 12:30 UTC |
Fitzpatrick Alexander AGeneral Counsel and Secretary
|
Tax withholdingCommon Stock | 7,802 | $5.24 | $40,882.48 |
DisclosureSEC source: 0001618835-20-000111 · wf-form4_158895543229158.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,529 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 6, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 06, 2020 Filed May 8, 2020 16:31 UTC |
Culwell KellyChief Medical Officer
|
Tax withholdingCommon Stock | 7,792 | $5.24 | $40,830.08 |
DisclosureSEC source: 0001618835-20-000114 · wf-form4_158895549907652.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,434 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 6, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 01, 2020 Filed May 2, 2020 00:12 UTC |
Culwell KellyChief Medical Officer
|
SaleCommon Stock | 1,000 | $4.75 | $4,750.00 |
DisclosureSEC source: 0001618835-20-000096 · wf-form4_158837835074185.xml · nonDerivative · entry 2 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,226 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 25, 2019. Read SEC document |
| April 30, 2020 Filed May 2, 2020 00:12 UTC |
Culwell KellyChief Medical Officer
|
SaleCommon Stock | 1,000 | $4.66 | $4,660.00 |
DisclosureSEC source: 0001618835-20-000096 · wf-form4_158837835074185.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,226 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 25, 2019. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 16:11 UTC |
Lynch Thomas GDirector
|
GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-20-000073 · wf-form4_158577186560857.xml · derivative · entry 3 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. F3 · derivative.exercise_date: The restricted stock units shall vest in four equal installments on June 30, 2020, September 30, 2020, December 31, 2020 and March 31, 2021. F3 · derivative.expiration_date: The restricted stock units shall vest in four equal installments on June 30, 2020, September 30, 2020, December 31, 2020 and March 31, 2021. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 16:11 UTC |
Lynch Thomas GDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-20-000073 · wf-form4_158577186560857.xml · derivative · entry 2 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 16:11 UTC |
Lynch Thomas GDirector
|
Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-20-000073 · wf-form4_158577186560857.xml · nonDerivative · entry 1 Lynch Thomas G · CIK 0001360000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 01:22 UTC |
Rarick Lisa DaleDirector
|
GrantStock option (right to buy) · Derivative | 75,000 | $0.00 Strike: $5.85 | $0.00 |
DisclosureSEC source: 0001618835-20-000037 · wf-form4_158276652169035.xml · derivative · entry 1 Rarick Lisa Dale · CIK 0001803550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-02-25 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest on a monthly basis over 3 years upon completion of continuous service for the Issuer from the vesting commencement date of February 25, 2020. The option was awarded in connection with Dr. Rarick's appointment to the Issuer's Board of Directors. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 19:10 UTC |
Culwell KellyChief Medical Officer
|
SaleCommon Stock | 1,000 | $7.00 | $7,000.00 |
DisclosureSEC source: 0001618835-20-000028 · wf-form4_158231222323693.xml · nonDerivative · entry 1 Culwell Kelly · CIK 0001726183 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,226 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 25, 2019. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 19:10 UTC |
Barrans RussellChief Commercial Officer
|
SaleCommon Stock | 14,957 | $6.50 | $97,220.50 |
DisclosureSEC source: 0001618835-20-000027 · wf-form4_158231220248237.xml · nonDerivative · entry 1 Barrans Russell · CIK 0001726184 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,240 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.